EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics Holdings plc announces the proposed placing of up to 42,205,707 new ordinary shares of 1 penny each in the Company by way of an accelerated book build (the “Placing”).
Christopher Mills, EKF’s Non-Executive Chairman, will make a statement at the Company’s Annual General Meeting to be held at 11.00am today.
Disclosures in accordance with the AIM Rules following the announcement on 8 April 2016 that Christopher Mills had been appointed as Non-Executive Chairman.
EKF Diagnostics announces that it has served notice to redeem the £3 million convertible loan from Zwanziger Family Ventures LLC .
EKF Diagnostics Holdings plc announces its unaudited final results for the year ended 31 December 2015.